Immutep Limited Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Immutep Limited
Access all reports
Immutep Limited is a clinical-stage biotechnology company, recognized for its pioneering work in developing novel immunotherapy for cancer and autoimmune diseases. The company's research and development efforts are centered on Lymphocyte Activation Gene-3 (LAG-3), a crucial cell surface molecule that plays a significant role in regulating the immune system. Immutep's portfolio includes a range of innovative immunotherapies designed to either stimulate or suppress the immune system to combat cancer or autoimmune diseases. The company is headquartered in Sydney, Australia, and its shares are listed on the Nasdaq.
Latest articles
The World of Luxury: Creating and Selling Desirability
Dive into the enchanting world of high-end allure, where the art of exclusivity shapes desire, turning luxury into an emblem of unique prestige.
6 May 2024
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
3 May 2024
Microsoft's Journey to Becoming the World's Most Valuable Company
Explore Microsoft's rise from a garage startup to the world's most valuable company, highlighting Bill Gates' role in shaping the digital revolution.
3 May 2024
Ticker symbol
Country
đŠđș Australia